|AHFS/Drugs.com||Consumer Drug Information|
|Chemical and physical data|
|Molar mass||75.07 g·mol−1|
|3D model (JSmol)|
Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by urease; it thus disrupts the bacteria's metabolism through competitive inhibition.
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983. AHA cannot be patented because it is a standard chemical compound.
- Fishbein, W; Carbone, P (1965). "Urease catalysis. ii. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid". J Biol Chem. 240: 2407–2414. PMID 14304845.
- Marwick, Charles (1983). "New drugs selectively inhibit kidney stone formation". The Journal of the American Medical Association. 240 (3): 321–322. doi:10.1001/jama.1983.03340030003001.